Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib.
Nishimoto KoshiroSuguru ShirotakeYu MiyamaGo KanekoKent KanaoDaisuke IgarashiTakayuki TakahashiYuta UmezawaMasanori YasudaMasafumi OyamaPublished in: IJU case reports (2022)
The survival benefit in the present case may be due to the initial potent anti-cancer effects of axitinib and durable immune effects of pembrolizumab, leading to long-term treatment-free survival.